{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470606762
| IUPAC_name = ''N''-<nowiki/>{4-[(Ethanethioamidoimino)methyl]phenyl}acetamide
| image = Thioacetazone.svg
| alt = Structural formula of thioacetazone
| width = 250
| image2 = Thioacetazone 3D spacefill.png
| alt2 = Space-filling model of thioacetazone
| width2 = 225

<!--Clinical data-->
| tradename = Conteben
| Drugs.com = {{drugs.com|international|thioacetazone}}
| routes_of_administration = Oral

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 104-06-3
| ATC_prefix = J04
| ATC_suffix = AM04
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 375492
| PubChem = 9568512
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7843221
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MMG78X7SSR
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08584

<!--Chemical data-->
| C=10 | H=12 | N=4 | O=1 | S=1 
| smiles = O=C(Nc1ccc(cc1)\C=N\NC(=S)N)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SRVJKTDHMYAMHA-WUXMJOGZSA-N
| synonyms = Thiacetazone; Thiocetazone; Thioparamizone; Benzothiozane; 4-Acetylaminobenzaldehyde thiosemicarbazone; ''N''-[4-[(Carbamothioylhydrazinylidene) methyl]phenyl]acetamide
}}

'''Thioacetazone''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]), also known as '''amithiozone''' ([[United States Adopted Name|USAN]]), is an [[oral administration|oral]] [[antibiotic]] which is used in the treatment of [[tuberculosis]].<ref name="Buckingham1993">{{cite book|author=John Buckingham|title=Dictionary of Natural Products|url=https://books.google.com/books?id=1W0NUD42fA4C&pg=PA208|date=2 December 1993|publisher=CRC Press|isbn=978-0-412-46620-5|pages=208–}}</ref><ref>Martindale, The Extra Pharmacopoeia, 30th ed, p. 217</ref><ref name="Drugs.com">https://www.drugs.com/international/thioacetazone.html</ref><ref name="GraysonCrowe2010" /> It has fallen into almost complete disuse due to [[toxicity]] and the introduction of improved [[Tuberculosis management#Drugs|anti-tuberculosis drug]]s like [[isoniazid]].<ref name="DonaldHelden2011">{{cite book|author1=Peter R. Donald|author2=Paul D. Van Helden|title=Antituberculosis Chemotherapy|url=https://books.google.com/books?id=r37jwNmr4sMC&pg=PA92|year=2011|publisher=Karger Medical and Scientific Publishers|isbn=978-3-8055-9627-5|pages=92–}}</ref> The drug has only weak activity against ''[[Mycobacterium tuberculosis]]'' and is only useful in preventing resistance to more powerful drugs such as isoniazid and [[rifampicin]]. It is never used on its own to treat tuberculosis;  it is used in a similar way to [[ethambutol]].

There is no advantage to using thioacetazone if the regimen used already contains ethambutol, but many countries in sub-Saharan Africa still use thioacetazone because it is extremely cheap.  Use of thioacetazone is declining because it can cause severe (sometimes fatal) skin reactions in HIV positive patients.<ref name="Rieder2001">{{cite journal
| vauthors=Rieder HL, Arnadottir T, Trebucq A, Enarson DA
| title=Tuberculosis treatment: dangerous regimens?
| journal=Int J Tuberc Lung Dis
| year=2001
| volume=5
| issue=1
| pages=1&ndash;3
| pmid=11263509 }}</ref><!--
--><ref name="Nunn1993">{{cite journal
| vauthors=Nunn P, Porter J, Winstanley P
| title=Thiacetazone&mdash;avoid like poison or use with care?
| journal=Trans R Soc Trop Med Hyg
| year=1993
| volume=87
| issue=5
| pages=578&ndash;82
| pmid=7505496
| doi=10.1016/0035-9203(93)90096-9 }}</ref>

The [[biological target]] of thioacetazone has proven elusive and its [[mechanism of action]] remains unknown, although it is thought to interfere with [[mycolic acid]] [[biosynthesis|synthesis]].<ref name="GraysonCrowe2010">{{cite book |author1= M Lindsay Grayson |author2=Suzanne M Crowe |author3= James S McCarthy |author4= John Mills, Johan W Mouton, S Ragnar Norrby, David L Paterson, Michael A Pfaller |title= Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs |url= https://books.google.com/books?id=XR3cBQAAQBAJ&pg=PA1673 |date= 29 October 2010 |publisher= CRC Press |isbn= 978-1-4441-4752-0 |pages= 1673–}}</ref>

==Adverse effects==
One of the documented adverse effects of thioacetazone is the excessive accumalation of serum (or [[blood plasma]]) in the brain. Another is weakening of the thyroid glands. These were found in a treatment combining conteben with PAS acid p-amino-salicylic acid.<ref>{{cite journal | url = http://www3.interscience.wiley.com/journal/122317107/abstract?CRETRY=1&SRETRY=0 | title = Hypothyroidism and Cerebral Edema Following Combined Treatment of Tuberculosis with Conteben (TB I 698) and p-Amino-Salicylic Acid | date = 12 January 1952 | doi = 10.1111/j.0954-6820.1952.tb14267.x | author = N. Bergqvist and De O. Mare}}</ref>

==References==
<references/>

==External links==
* [http://www.chemindustry.com/chemicals/013633964.html Chemindustry]
* [http://www.spiegel.de/spiegel/print/d-20300776.html "Im November 1947 macht der für alles Neue aufgeschlossene Freiburger Internist Professor Dr. Ludwig Heilmeyer, ein Mitschüler des Atomphysikers Heisenberg, die erste schwache Andeutung, daß sich Domagks Präparat in seiner Klinik zu bewähren scheine. Genaue Zahlen gibt aber erst drei Monate später ein bis dahin unbekannter Arzt, Dr. Berthold Mikat, der nur in Vertretung seines Chefs, Dr. Fritz Kuhlmann aus Mölln, spricht: Im Krankenhaus der Landesversicherungsanstalt Schleswig-Holstein ist nach Tb I-Behandlung bei 49 von 66 Patienten mit Lungentuberkulose eindeutige Besserung nachgewiesen worden. Das ist der Start für die Einführung des Tb I, das später den Namen Conteben bekommt."]

{{Antibiotics}}

[[Category:Antibiotics]]
[[Category:Anti-tuberculosis drugs]]
[[Category:Acetanilides]]
[[Category:Thioureas]]
[[Category:Thiosemicarbazone]]